Paradigm Biopharmaceuticals Limited (ASX:PAR)

Australia flag Australia · Delayed Price · Currency is AUD
0.2600
-0.0080 (-3.08%)
Mar 11, 2026, 4:10 PM AEST
Market Cap114.21M -46.2%
Revenue (ttm)8.45K -49.4%
Net Income-36.09M
EPS-0.10
Shares Out439.25M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume585,331
Average Volume1,000,292
Open0.2600
Previous Close0.2600
Day's Range0.2500 - 0.2600
52-Week Range0.2400 - 0.4920
Beta0.18
RSI38.16
Earnings DateFeb 25, 2026

About ASX:PAR

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol PAR
Full Company Profile

Financial Performance

Financial Statements